Today: 31 January 2026
Subscribe
Browse Category

Business News News 4 November 2025 - 6 November 2025

CarMax (KMX) Ousts CEO Bill Nash, Warns of Weak Q3; Shares Slide ~12% — Nov. 6, 2025

CarMax (KMX) Ousts CEO Bill Nash, Warns of Weak Q3; Shares Slide ~12% — Nov. 6, 2025

CarMax (NYSE: KMX) said its board terminated CEO Bill Nash effective Dec. 1 and named director David McCreight interim CEO. The used‑car giant also issued a downbeat Q3 outlook, sending KMX shares lower on Nov. 6, 2025. CarMax, Inc. announced sweeping leadership changes and a sharply weaker preliminary outlook for its fiscal third quarter ending Nov. 30, 2025: Key takeaways…
6 November 2025
···
McConnell’s Hemp Crackdown Collides With Retail THC Boom: Big Brands, 39 AGs, and Congress Face a ‘Hemp War’ (Nov. 6, 2025)

McConnell’s Hemp Crackdown Collides With Retail THC Boom: Big Brands, 39 AGs, and Congress Face a ‘Hemp War’ (Nov. 6, 2025)

Why this matters now The seven‑year experiment that legalized hemp (2018 Farm Bill) has morphed into a high‑stakes fight over hemp‑derived intoxicants such as delta‑8, delta‑10, THCA and other cannabinoids. Today, big CPG and alcohol interests publicly pressed Congress to close the “hemp loophole,” while states tightened rules or imposed temporary bans. At the same time, major retailers are normalizing…
6 November 2025
Arm Holdings (ARM) Beats Q2, Lifts Q3 Outlook on AI Momentum — What to Know Today (Nov. 6, 2025)

Arm Holdings (ARM) Beats Q2, Lifts Q3 Outlook on AI Momentum — What to Know Today (Nov. 6, 2025)

Why Arm is rallying today Arm delivered another “beat‑and‑raise” quarter as AI workloads continue to shift toward Arm’s power‑efficient compute. Revenue of $1.14B (+34% YoY) topped expectations, while non‑GAAP EPS of $0.39 cleared the Street. Management guided Q3 well above consensus, citing broad‑based strength across smartphones, automotive, IoT—and especially data centers, where hyperscalers are standardizing around Arm for performance‑per‑watt gains.…
6 November 2025
····
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

Key takeaways What happened today (Nov. 6) 1) Court clears the way for Metsera to pivot to Novo’s richer bid.On Wednesday evening, the Delaware Chancery Court denied Pfizer’s TRO request that sought to keep Metsera bound to its earlier merger agreement with Pfizer. In a same‑day statement, Pfizer argued the decision “does not address the merits” and vowed to pursue…
6 November 2025
····
JELD‑WEN to cut 850 jobs and trims 2025 outlook after deep Q3 loss; Europe business under strategic review

JELD‑WEN to cut 850 jobs and trims 2025 outlook after deep Q3 loss; Europe business under strategic review

Date: Nov. 6, 2025 Key takeaways What’s new today (Nov. 6) Following Monday’s earnings release, JELD‑WEN confirmed it will shed ~850 positions across North America and corporate functions and is reviewing strategic alternatives for its Europe segment. The workforce actions, slated to be completed by the end of 2025, are part of a broader cost‑reset amid weaker demand and price‑cost…
6 November 2025
··
OpenAI’s DevDay Bombshells: No-Code AgentKit, ChatGPT App Store & Jony Ive’s AI Vision

OpenAI News Today (Nov 5, 2025): 1M Business Customers, SoftBank JV in Japan, and Turner’s ‘Wall‑to‑Wall’ ChatGPT Rollout

Published: November 5, 2025 TL;DR OpenAI crosses 1 million business customers OpenAI announced that more than 1 million organizations now pay for its products—either ChatGPT for Work or via its developer platform—calling it “the fastest‑growing business platform in history.” The company also highlighted momentum metrics such as 7 million total ChatGPT for Work seats (up ~40% in two months) and…
5 November 2025
··
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Company Overview & Stock Snapshot Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence for its COVID-19 vaccine (Comirnaty) and antiviral pill (Paxlovid). However, with the pandemic’s tide receding, Pfizer’s stock (PFE) has faced…
5 November 2025
····
China Import Expo 2025 Shatters Records: $40B Deals, US Firms Return After Xi–Trump Summit – Experts Sound Off

China Import Expo 2025 Shatters Records: $40B Deals, US Firms Return After Xi–Trump Summit – Experts Sound Off

Expo Highlights & Speeches The CIIE is China’s flagship trade fair to demonstrate “free trade credentials” and attract imports Reuters Scmp. Premier Li stressed high-level opening-up, promising to keep China’s economy “fairer and more transparent” Reuters. Reuters notes Li said rising tariffs “are seriously undermining international economic and trade rules” Reuters. He repeated China’s commitment to increase imports of “high…
5 November 2025
····
McDonald’s Q3 Earnings: Snack Wrap Comeback Drives Sales — Is Stock Primed to Soar?

McDonald’s Q3 Earnings: Snack Wrap Comeback Drives Sales — Is Stock Primed to Soar?

Robust Sales Amid Value Push McDonald’s third-quarter report topped sales forecasts, thanks largely to customer spending per visit. U.S. sales growth (2.4%) exceeded last year’s 0.3%, as diners took advantage of limited-time deals Newsmax Newsmax. International markets also turned in strong comps (e.g. Japan +4.7%, Germany +4.3%) Newsmax. The company’s global systemwide sales reached over $36 billion (an 8% increase,…
5 November 2025
··
AI & Quantum Frenzy Propels IBM Stock to New Heights – Will the Rally Last?

IBM’s Shock Q4 Layoffs: Thousands of Jobs Cut as Big Blue Doubles Down on AI and Software—What It Means for You and the Stock

Key facts (Nov. 5, 2025) What happened and why now IBM confirmed it is cutting jobs in the fourth quarter of 2025, affecting “thousands” of employees. The company framed the move as a routine workforce rebalance to align headcount with areas where it sees stronger, more profitable growth—namely software, hybrid cloud (Red Hat), and AI‑driven services. Reuters Bloomberg first reported…
5 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Once Sky-High Valuation Falters Amid Weight-Loss Drug Headwinds Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market value Reuters. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic (both containing the GLP-1 agonist semaglutide) became global sensations,…
5 November 2025
···
Axon Stock Rockets 420% Overseas as Wall Street Targets $1,000 – Should You Buy the Dip?

Axon Enterprise Rockets Past Revenue Goals – But EPS Miss Sends Stock Reeling

Q3 2025 Earnings Report Axon’s Q3 results (announced Oct. 31) beat revenue expectations but showed a small profit shortfall. The company “delivered another record quarter, with revenue growing 31% year over year to $711 million” Prnewswire, marking its seventh straight quarter above 30% growth. Sales growth was driven by the software business – Axon’s Software & Services segment grew 41%…
4 November 2025
···
1 … 63 64 65 66 67 … 80

Stock Market Today

  • Nexa Resources Share Price Rally Underpinned by Discounted Cash Flow Valuation
    January 31, 2026, 2:55 PM EST. Nexa Resources (NEXA) shares trade at $12.61, showing significant gains-up 106.3% over one year-despite recent volatility. A Discounted Cash Flow (DCF) model, which estimates company value by projecting future cash flows and discounting them to present value, indicates the stock is 54.1% undervalued with a fair value of $27.44. The model forecasts free cash flow rising from $7.6 million to $281 million by 2030 and $365.4 million by 2035. Additionally, the price-to-sales ratio stands at 0.59x, below the metals and mining sector average, suggesting potential undervaluation relative to peers. These valuation measures provide investors a basis to reassess Nexa amid broader market movements and its strong recent returns.
Go toTop